RecruitingAtrial FibrillationObesity
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.
Sponsor: The Cleveland Clinic
You may qualify if…
- ✓ Subjects eligible for inclusion in this study must meet all of the following criteria:
- ✓ 1. Sinus rhythm at randomization
- ✓ 1. Sustained normal sinus rhythm (or)
- ✓ 2. Normal sinus rhythm at office visit
- ✓ 2. Age ≥18 to ≤80 years old
- ✓ 3. BMI ≥ 27 and ≤60 kg/m2
- ✓ 4. AFIB criteria:
- ✓ 1. Must be documented by ECG or monitor.
You may not qualify if…
- ✕ Subjects meeting any of the following criteria are not eligible for inclusion in this study.
- ✕ 1. AFIB ablation within the last 6 months
- ✕ 2. Planned ablation prior to 3 months post randomization
- ✕ 3. Significant cardiac valvular disease with planned cardiac valve intervention/surgery in the next 12 months
- ✕ 4. Severe uncompensated cardiopulmonary disease
- ✕ 5. New York Heart Association Class III or IV
- ✕ 6. Left ventricular ejection fraction \<35% at the time of screening
- ✕ 7. Hospitalization in the past 6 months for myocardial infarction, unstable angina, stroke, transient ischemic attack, or heart surgery
Where it's recruiting
Ohio
Cleveland
Source: ClinicalTrials.gov · NCT06802081 · last updated 2026-01-13